EUVIMEDObjevte EUVIMED
Open access

Engineering an ACE2-Derived Fragment as a Decoy for Novel SARS-CoV-2 Virus

Fabiana Renzi, Austin Seamann, Koelina Ganguly, Kabita Pandey, Siddappa N Byrareddy iD, Surinder Batra, Sushil Kumar, Dario Ghersi iD

ACS Pharmacology & Translational Science · 2023-06-09 · 6 (6) · 857-867

DOI: 10.1021/acsptsci.2c00180 ↗

At a glance

Journal article in ACS Pharmacology & Translational Science, published online on 2023-05-22. Written by Fabiana Renzi and 7 co-authors. Institution: Department of Physics, Università di Roma "La Sapienza", 00185 Rome, Italy. Cited 9 times so far (Crossref); 40 references. The full text is freely available in PubMed Central. Funded by: NIAID NIH HHS, NIDA NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstraktBibliografické údajeCiteRelated studies

Abstract (original language)

Entry inhibitors are an important resource in the response against emerging pathogens like the novel SARS-CoV-2, which enters human cells via interaction between the surface spike glycoprotein and the cellular membrane receptor angiotensin-converting enzyme 2 (ACE2). Using a combination of comparative structural analyses of the binding surface of the spike to ACE2, docking experiments, and molecular dynamics simulations, we identified a stable fragment of ACE2 that binds to the spike, is soluble, and is not predicted to bind to its physiological ligand angiotensin II. From this fragment we computationally designed and experimentally validated a smaller, stable peptide that disrupts ACE2-spike interaction at nanomolar concentrations, suggesting its potential use as a decoy that could interfere with viral binding by competition.

Authors and institutions

  • Department of Physics, Università di Roma "La Sapienza", 00185 Rome, Italy.
  • School of Interdisciplinary Informatics, University of Nebraska at Omaha, Omaha, Nebraska 68182, USA.
  • Department of Biochemistry & Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska 68182, USA.
  • Department of Pharmacology & Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska 68182, USA.

ORCID profiles: Siddappa N Byrareddy, Dario Ghersi

Funding

  • NIAID NIH HHS
  • NIDA NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • University of Nebraska Omaha
  • National Institute on Drug Abuse
  • COVID-19 Rapid Response
  • University of Nebraska System

Cite

APA

Renzi, F., Seamann, A., Ganguly, K., Pandey, K., Byrareddy, S. N., Batra, S., Kumar, S., & Ghersi, D. (2023). Engineering an ACE2-Derived Fragment as a Decoy for Novel SARS-CoV-2 Virus. ACS Pharmacology & Translational Science, 6(6), 857-867. https://doi.org/10.1021/acsptsci.2c00180

Vancouver

Renzi F, Seamann A, Ganguly K, Pandey K, Byrareddy SN, Batra S, et al. Engineering an ACE2-Derived Fragment as a Decoy for Novel SARS-CoV-2 Virus. ACS Pharmacology & Translational Science. 2023;6(6):857-867. doi:10.1021/acsptsci.2c00180

BibTeX
@article{Renzi2023,
  author = {Renzi, Fabiana and Seamann, Austin and Ganguly, Koelina and Pandey, Kabita and Byrareddy, Siddappa N and Batra, Surinder and Kumar, Sushil and Ghersi, Dario},
  title = {Engineering an ACE2-Derived Fragment as a Decoy for Novel SARS-CoV-2 Virus},
  journal = {ACS Pharmacology & Translational Science},
  year = {2023},
  volume = {6},
  number = {6},
  pages = {857--867},
  doi = {10.1021/acsptsci.2c00180}
}
Start for free →